Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022011021 - USE OF CONSERVED PEPTIDE EPITOPES FROM SARS-COV-2 FOR THE DEVELOPMENT OF A BROAD COVID-19 VACCINE

Publication Number WO/2022/011021
Publication Date 13.01.2022
International Application No. PCT/US2021/040700
International Filing Date 07.07.2021
IPC
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
C07K 14/165 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Applicants
  • ASCENDO BIOTECHNOLOGY, INC. [CN]/[CN]
  • LEE, Frank Wen-Chi [US]/[US]
Inventors
  • LU, Yen-Ta
  • CHANG, Chia-Ming
  • HUANG, Ping-Yen
Agents
  • LIANG, T. Chyau
Priority Data
63/048,65507.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) USE OF CONSERVED PEPTIDE EPITOPES FROM SARS-COV-2 FOR THE DEVELOPMENT OF A BROAD COVID-19 VACCINE
(FR) UTILISATION D'ÉPITOPES PEPTIDIQUES CONSERVÉS DE SARS-COV-2 POUR LE DÉVELOPPEMENT D'UN VACCIN À LARGE SPECTRE CONTRE LA COVID-19
Abstract
(EN) A vaccine for generation of immunity against SARS-CoV-2 infection includes an S2'-peptide of SARS-CoV-2 in a formulation that enhances immune responses, wherein the S2'-peptide includes the amino acid sequence selected from SEQ ID NO: 1-10. The formulation includes nanocomplexes encapsulating the S2'-peptide, or the formulation includes TREM-like transcript-1 (TREML1) extracellular domain (ECD) or a stalk peptide as an immune booster.
(FR) Un vaccin permettant la génération d'une immunité contre une infection par le SARS-CoV-2 comprend un peptide S2' du SARS-CoV-2 dans une formulation qui améliore les réponses immunitaires, le peptide S2' comprenant la séquence d'acides aminés choisie parmi SEQ ID No : 1 à 10. La formulation comprend des nanocomplexes encapsulant le peptide S2', ou la formulation comprend le domaine extracellulaire du transcrit 1 de type TREM (TREML1) ou un peptide tige en tant qu'amplificateur immunitaire.
Latest bibliographic data on file with the International Bureau